Conflict of Interest: none.
Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer
Article first published online: 16 JUL 2013
Copyright © 2013 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 108, Issue 4, pages 230–235, September 15, 2013
How to Cite
Lou, X., Qi, X., Zhang, Y., Long, H. and Yang, J. (2013), Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer. J. Surg. Oncol., 108: 230–235. doi: 10.1002/jso.23380
Xiaolou Lou and Xiaoliang Qi contributed equally to this work and should be considered as co-first authors.
- Issue published online: 16 AUG 2013
- Article first published online: 16 JUL 2013
- Manuscript Accepted: 21 JUN 2013
- Manuscript Received: 1 MAY 2013
- colorectal cancer;
MicroRNAs (miRNAs) play an essential role in colorectal cancer (CRC) development and progression. Aberrant miR-625 expression has been reported in several cancers. However, the clinical significance of miR-625 in human CRC has not been addressed.
miR-625 expression was determined in 96 pairs of primary CRC and their corresponding adjacent nontumor tissues by quantitative reverse transcriptase-polymerase chain reaction. Associations of miR-625 expression with demographic and clinicopathologic features were determined. Additionally, the effects of ectopic expression of miR-625 on cell migration and invasion were investigated in vitro and in vivo.
miR-625 was significantly downregulated in CRC tissues and cell lines. In addition, the decreased expression of miR-625 was positively associated with advanced lymph node metastasis (P = 0.038), liver metastasis (P = 0.031), poor overall survival (P = 0.002), and an unfavorable prognosis for CRC patients, as determined through a multivariate analysis (P = 0.034). Moreover, functional assays demonstrated that ectopic miR-625 expression inhibits the invasion and migration of HCT116 CRC cells both in vitro and in vivo.
Our results suggest that miR-625 may serve as an efficient clinical biomarker and a therapeutic tool for the inhibition of metastasis in CRC. J. Surg. Oncol. 2013 108:230–235. © 2013 Wiley Periodicals, Inc.